Your browser is no longer supported. Please, upgrade your browser.
CKPT Checkpoint Therapeutics, Inc. daily Stock Chart
Checkpoint Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.16 Insider Own9.40% Shs Outstand36.07M Perf Week-6.60%
Market Cap127.69M Forward P/E- EPS next Y-1.15 Insider Trans- Shs Float20.82M Perf Month-4.58%
Income-30.70M PEG- EPS next Q-0.30 Inst Own12.60% Short Float2.04% Perf Quarter58.74%
Sales0.80M P/S159.61 EPS this Y3.80% Inst Trans5.16% Short Ratio6.27 Perf Half Y-7.09%
Book/sh0.75 P/B4.72 EPS next Y4.20% ROA-104.30% Target Price15.50 Perf Year-18.43%
Cash/sh0.82 P/C4.31 EPS next 5Y- ROE-139.00% 52W Range1.50 - 6.29 Perf YTD94.51%
Dividend- P/FCF- EPS past 5Y- ROI-151.80% 52W High-43.72% Beta-
Dividend %- Quick Ratio3.50 Sales past 5Y- Gross Margin- 52W Low136.00% ATR0.37
Employees6 Current Ratio3.50 Sales Q/Q-98.60% Oper. Margin- RSI (14)53.29 Volatility7.67% 8.78%
OptionableNo Debt/Eq0.00 EPS Q/Q-22.90% Profit Margin- Rel Volume0.57 Prev Close3.75
ShortableYes LT Debt/Eq0.00 EarningsNov 02 Payout- Avg Volume67.77K Price3.54
Recom- SMA20-3.19% SMA5025.06% SMA20015.93% Volume38,586 Change-5.60%
Dec-08-17Initiated H.C. Wainwright Buy $11
Jan-07-19 08:30AM  Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301 GlobeNewswire +12.50%
Dec-25-18 02:39PM  Are Checkpoint Therapeutics, Inc.s (NASDAQ:CKPT) Interest Costs Too High? Simply Wall St.
Nov-02-18 09:15AM  Checkpoint Therapeutics, Inc. (CKPT) Reports Q3 Loss, Lags Revenue Estimates Zacks
08:00AM  Checkpoint Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Oct-26-18 10:30AM  Checkpoint Therapeutics, Inc. (CKPT) Q3 Earnings Preview: What to Watch Ahead of the Release Zacks
Oct-16-18 08:00AM  Checkpoint Therapeutics Appoints Christian Béchon to its Board of Directors GlobeNewswire +5.93%
Oct-09-18 01:54PM  Do Institutions Own Shares In Checkpoint Therapeutics Inc (NASDAQ:CKPT)? Simply Wall St. -9.34%
Sep-27-18 08:00AM  Checkpoint Therapeutics to Present at Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-25-18 08:00AM  Checkpoint Therapeutics Announces Presentation of Updated Data from Phase 1/2 Trial of EGFR Inhibitor CK-101 GlobeNewswire -19.12%
Sep-07-18 12:25PM  CKPT: Second Mover Could Have First Class Advantage Zacks Small Cap Research
Sep-06-18 07:30AM  Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101 GlobeNewswire -11.11%
Aug-30-18 08:00AM  Checkpoint Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire +6.02%
Aug-13-18 10:30AM  CKPT: CK-101 Data Announced Zacks Small Cap Research
08:00AM  Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer GlobeNewswire
Aug-08-18 07:30AM  Checkpoint Therapeutics, Inc. (CKPT) Reports Q2 Loss, Misses Revenue Estimates Zacks -5.34%
Aug-07-18 04:30PM  Checkpoint Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire +6.50%
Aug-02-18 10:29AM  Special Report: Biotech incubator taps investors through in-house brokerage Reuters +5.06%
Jun-28-18 10:25AM  CKPT: Checkpoint Inhibitors: Dominating the Immuno-Oncology Space Zacks Small Cap Research
Jun-04-18 08:00AM  Checkpoint Therapeutics to Participate in June Investor Conferences GlobeNewswire
May-10-18 04:30PM  Checkpoint Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Apr-18-18 09:00AM  Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-05-18 08:38AM  Why Checkpoint Therapeutics (CKPT) Might Be a Diamond in the Rough Zacks
Mar-21-18 08:00AM  Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301 GlobeNewswire
Mar-19-18 07:40AM  Blog Exposure - Checkpoint Therapeutics to Present Preclinical Data on its BET Inhibitor CK-103 at AACR Meeting ACCESSWIRE
Mar-15-18 04:05PM  Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights GlobeNewswire
07:30AM  Checkpoint Therapeutics Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-13-18 07:45AM  Checkpoint Therapeutics to Participate in March Investor Conferences GlobeNewswire
Mar-08-18 09:00AM  Checkpoint Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock GlobeNewswire -11.99%
Mar-07-18 04:05PM  Checkpoint Therapeutics, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-06-18 08:30AM  Checkpoint Therapeutics to Present at BIO CEO & Investor Conference GlobeNewswire
Jan-03-18 07:30AM  Checkpoint Therapeutics to Present at Biotech Showcase 2018 GlobeNewswire -6.48%
Dec-14-17 07:30AM  Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 10, 2018 GlobeNewswire -6.72%
Dec-08-17 10:42AM  Checkpoint Therapeutics Wins A New Bull As Company's 'Plan Is Quickly Coming Together' Benzinga +21.26%
Dec-06-17 02:20PM  CKPT: A Smokin Opportunity in PD-L1 Therapy and Beyond Zacks Small Cap Research +13.86%
Oct-05-17 09:00AM  Checkpoint Therapeutics (CKPT) Starts CK-301 Trials Zacks Small Cap Research -10.91%
07:30AM  Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301 GlobeNewswire
Sep-20-17 08:00AM  Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire
Sep-12-17 11:00AM  Checkpoint Inhibitors Are Hot, and CKPT Has Something in the Oven Zacks Small Cap Research -5.06%
Sep-11-17 08:30AM  Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer GlobeNewswire
Sep-05-17 08:00AM  Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Jul-28-17 10:00AM  Checkpoint (CKPT): An Innovator of Immune-Enhanced Combination Therapies in Solid Tumors Zacks Small Cap Research
Jun-26-17 08:00AM  Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market GlobeNewswire
Feb-28-17 07:00AM  Checkpoint Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CKPT-US : February 28, 2017 Capital Cube +42.86%
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's products include CK-301 in Phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC); and CK-101 in the Phase 1 portion of a Phase 1/2 clinical trial for the treatment of epidermal growth factor receptor (EGFR) mutation-positive NSCLC. Its pipeline consists of glucocorticoid-induced TNFR-related protein; and carbonic anhydrase IX. The company is also developing three oral, small-molecule, targeted anti-cancer agents that inhibit epidermal growth-factor receptor mutations, the bromodomain and extra-terminal protein, and poly polymerase. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the Anti-PD-L1 and Anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.